Article Text
PDFA difficult case
Rituximab for corticosteroid-resistant relapsing IgG4-related intracranial pachymeningitis: report of two cases
Abstract
IgG4-related disease is now recognised as an important cause of intracranial and spinal hypertrophic pachymeningitis. Treatment with corticosteroids generally leads to significant clinical improvement. We present two cases of IgG4 pachymeningitis unresponsive to corticosteroids who improved with rituximab.
- neuroimmunology
- neuroophthalmology
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Advances in the diagnosis and management of IgG4 related disease
- IgG4-related disease: a rare but treatable cause of refractory intracranial hypertension
- Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations
- IgG4-related hypertrophic pachymeningitis with chronic subdural haematoma
- Intracranial spread of IgG4-related disease via skull base foramina
- A case of multiple cranial nerve palsies
- Ocular adnexal IgG4-related disease: CT and MRI findings
- Rituximab for IgG4-related disease: a prospective, open-label trial
- Immunoglobulin G4-related intracranial inflammatory pseudotumours along both the oculomotor nerves
- The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease